Fate Therapeutics Inc FATE:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 1:21 PM EDT
4.26quote price arrow up+0.04 (+1.07%)
Volume
935,292
52 week range
1.63 - 8.83
Loading...
  • Open4.38
  • Day High4.50
  • Day Low4.18
  • Prev Close4.22
  • 52 Week High8.83
  • 52 Week High Date03/07/24
  • 52 Week Low1.63
  • 52 Week Low Date10/30/23

Key Stats

  • Market Cap485.428M
  • Shares Out113.82M
  • 10 Day Average Volume3.31M
  • Dividend-
  • Dividend Yield-
  • Beta1.94
  • YTD % Change13.77

KEY STATS

  • Open4.38
  • Day High4.50
  • Day Low4.18
  • Prev Close4.22
  • 52 Week High8.83
  • 52 Week High Date03/07/24
  • 52 Week Low1.63
  • 52 Week Low Date10/30/23
  • Market Cap485.428M
  • Shares Out113.82M
  • 10 Day Average Volume3.31M
  • Dividend-
  • Dividend Yield-
  • Beta1.94
  • YTD % Change13.77

RATIOS/PROFITABILITY

  • EPS (TTM)-1.91
  • P/E (TTM)-2.23
  • Fwd P/E (NTM)-2.19
  • EBITDA (TTM)-194.075M
  • ROE (TTM)-42.07%
  • Revenue (TTM)6.478M
  • Gross Margin (TTM)-
  • Net Margin (TTM)-2,933.79%
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date08/06/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Fate Therapeutics Inc

 

Profile

MORE
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders. Its proprietary induced pluripotent stem cells (iPSC) product platform combines multiplexed-engineering of human iPSCs with single-cell selection to create clonal master iPSC lines. The Company’s platform is designed to overcome numerous...
William Rastetter Ph.D.
Independent Chairman of the Board
John Wolchko
President, Chief Executive Officer, Director
Edward Dulac III
Chief Financial Officer
Cindy Tahl J.D.
General Counsel and Corporate Secretary
Address
12278 Scripps Summit Drive
San Diego, CA
92131
United States

Top Peers

SYMBOLLASTCHG%CHG
FULC
Fulcrum Therapeutics Inc
8.45+0.54+6.83%
SLRN
ACELYRIN Inc
4.88+0.14+3.07%
CRBP
Corbus Pharmaceuticals Holdings Inc
44.39+1.40+3.26%
ALLO
Allogene Therapeutics Inc
3.08+0.12+4.22%
KRRO
Korro Bio Inc
52.00+1.95+3.90%